Figure 1.
The effect of the CD34+ cell dose (× 106/kg) on (a) overall survival (OS), (b) transplant-related mortality (TRM), (c) relapse (d) acute graft-versus-host disease (GVHD) II-IV, (e) chronic GVHD and (f) GVHD and relapse-free survival (GRFS) in patients with malignant diseases who received a peripheral blood stem cell (PBSC) graft from a sibling donor. The p-values indicate differences between the 6–7 × 106/kg (OS, TRM, GRFS) or the <5 × 106/kg (Relapse, cGVHD) groups and all the others as found on multivariate analyzes.